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Abstract
Alterations in oncogenes are critical steps in the develop-
ment of endometrial cancer. To investigate the potential
clinical relevance of the amplification of the oncogenes
c-erbB2, c-myc, and int-2 and the mutation of K-ras in
endometrial cancer, 112 tumors were examined using
PCR-based fluorescent DNA technology. Amplification of
the three oncogenes and the mutation of K-ras were cor-
related with age, tumor size, lymph node status, metas-
tases, stage, histological types, grade, steroid hormone
receptor expression (estrogen receptor, ER; progester-
one receptor, PgR), family history of cancer, previous
history of cancer or precursor lesions, and previous his-
tory of hormone replacement therapy. Oncogene amplif-
ication of c-erbB2 was detected in 18.9%, of c-myc in
2.7% and of int-2 in 4.2%, and K-ras mutation in 11.6%.
No significant correlations could be detected between
amplification of c-erbB2 and any of the other parameters.
Mutation of K-ras is associated with positive expression
of PgR. This might indicate that mutation and activation
of K-ras are involved in the development of hormonal
independence in endometrial cancer.
Introduction
Endometrial cancer is the most abundant female geni-
tal cancer with a significant increase in the cause-specific
death rate over the last few years, which may reflect the
aging population [1, 2]. According to the FIGO classifica-
tion (1988), the staging of endometrial cancer is based
upon surgical findings. The three major criteria for thera-
peutic decisions include myometrial invasion, tumor
grading, and extrauterine tumor spread [3, 4]. The search
for prognostic and/or predictive factors in endometrial
cancer include DNA ploidy and S-phase [5, 6], expression
of the steroid hormone receptors [7–9], the epidermal
growth factor receptor, the Her-2/neu protein, and the
p53 protein [10–15]. In these studies tumors with high
FIGO classification showed decreased estrogen (ER) and
progesterone receptor (PgR) expression [7, 8] and in-
creased epidermal growth factor receptor, Her-2/neu, and
p53 expression [6, 11–15]. By univariant or multivariant
analyses, none of these parameters proved to be more rel-
evant than the three major prognostic parameters. Genet-
ic alterations in the development of endometrial carcino-
mas have not been well characterized, little is known
about oncogene and tumor suppressor gene activity in
these carcinomas. Cytogenetic and molecular genetic
analyses of endometrial cancer samples have found am-
plification of the c-erbB2 gene [10, 11], mutations in the
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p53 gene [14, 15], microsatellite instability and mutation
in the K-ras gene [16–19], deletion in the DCC gene [20],
and loss of heterozygosity at chromosomes 1p, 3p, 8p, 9p,
10q, 14q, 16q, 17q, and 18q [21–24]. The main focus of
these studies was directed towards their relevance for
tumor development and their role in the multistep carci-
nogenesis of endometrial cancer. They encompass a small
number of cases and do not focus on prognostic values or
correlations with histological or clinical parameters.
Gene amplification is a common mechanism of proto-
oncogene activation and is believed to play a key role in
neoplastic cell transformation and tumor progression.
Mutations in oncogenes are a rare phenomenon. In this
retrospective study, a rapid, non-radioactive, highly sensi-
tive approach based on differential PCR and fluorescent
DNA technology for quantitative determination of onco-
gene amplification in formalin-fixed, paraffin-embedded
endometrial carcinomas was established. Furthermore, a
fluorescence-based sequencing strategy was used for con-
firmation of single-strand conformation polymorphism
(SSCP) screened alterations in the K-ras oncogene.
Materials and Methods
Patient Characteristics, Surgical Procedures, and Adjuvant Thera-
py. The study included 112 patients who were treated for primary
endometrial cancer at the Department of Obstetrics and Gynecology,
Heinrich-Heine-University, Düsseldorf, from January 1980 to De-
cember 1994 and from whom complete follow-up data were avail-
able. An abdominal hysterectomy and bilateral oophorectomy were
performed in all patients. In 75 patients with advanced stage or palp-
able lymph nodes, lymphadenectomy was performed by removing
the lymphatic tissue along the external and internal iliac veins and
arteries, and in the obturator fossae. Para-aortic lymphadenectomy
was only performed in case of positive palpation. Patients with deep
myometrial invasion (150%) or undifferentiated tumors (G3) were
treated with postoperative brachytherapy to the vaginal vault. Eight
patients received external beam irradiation, 11 patients adjuvant
hormonal therapy (TAM, MPA), none chemotherapy. Staging was
performed according to the FIGO classification of 1988. Anamnestic
information included age, family history of gynecological or breast
cancer (at least 1 case), previous history of cancer or preceding
lesions, and history of hormonal therapy (oral contraceptives, hor-
mone replacement therapy). Patients were followed clinically for up
to 186 months (median 98 months). Recurrences were histologically
confirmed. Death reports were available.
Histology and DNA Extraction. Formalin-fixed, paraffin-embed-
ded blocks of tumor specimens and additional non-tumor tissue from
112 patients were analyzed. 93% of the tumors encompassed endo-
metrioid adenocarcinomas of various types (papillary, secretory, cil-
iated cell, adenoacanthoma, adenosquamous), 7% were clear cell,
serous or mucinous carcinoma. In addition, 5 different myometrium
samples randomly chosen from each year (1980–1994; total n = 90)
served as controls to test the influence of fixatives, or fixation time on
DNA quality. For tumor samples, hematoxylin-eosin staining was
used for a repeated pathologic evaluation (e.g. TNM status, myome-
trial invasion, grading, histological typing, lymph node involve-
ment). ER and PgR expression was determined and scored on newly
prepared 5-Ìm sections by immunohistochemistry [25]. The amount
of tumor cells in sections of endometrial carcinomas was estimated
by visual examination of 5-Ìm HE-stained sections. Adjacent 40-Ìm
toluidine-stained tumor sections with a high content of tumor cells
(170%) were used for microdissection [26]. DNA was extracted from
the tumor sections as previously described [27].
Amplification of c-erbB2, c-myc and int-2 Gene. Differential PCR
combined with fluorescent DNA technology was used for quantita-
tive determination of c-erbB2, c-myc and int-2 oncogene amplifica-
tion in tumor samples. PCR reactions, fragment analysis, and assess-
ment of oncogene amplification were performed as previously re-
ported [27, 28]. Briefly, the gene of interest and an unamplified refer-
ence gene (y-IFN) were amplified in a multiplex PCR using fluores-
cent-labelled primers. In each PCR experiment, DNA extracted from
normal placenta as reference tissue with non-amplified target genes
was included. PCR products were electrophoresed on an automated
fluorescent DNA sequencer (A.L.F.TM Pharmacia, Freiburg, Germa-
ny). Fluorescent emission data collected during the electrophoresis
were calculated using AlleleLinksTM software (Pharmacia). Amplifi-
cation of target genes in tumor tissue, which reflects the ratio of the
gene copy numbers of the oncogene and the y-IFN reference gene,
was estimated from the ratio of peak areas using placenta DNA for
normalization. Results of at least two independent assays were calcu-
lated with the equation: amplification n = (Pt/Pr)/(Pt placenta/Pr placenta),
where Pt = peak area of target gene signal and Pr = peak area of refer-
ence gene signal (y-IFN).
Mutation of the K-ras Gene. Mutation of the K-ras gene at codons
12/13 and 61 were examined by PCR-SSCP and direct sequencing.
Exon 1 and 2 of the K-ras gene were amplified by PCR using the
following primer pairs: for codon 12/13, 5)-CATGTTCTAATA-
TAGTCACA-3) (forward) and 5)-GTTATCTCCATTTAGAACAA-
3) (reverse); for codon 61, 5)-TTCCTACAGGAAGCAAGTAG-3)
(forward) and 5)-GATGAACGAAGGACATCCTT-3) (reverse).
PCR was performed in 50 Ìl with 2 Ìl of genomic DNA isolated from
paraffin sections, 40 pmol of each primer, 20 mM Tris-HCl (pH 8.4),
50 mM KCl, 1.5 mM MgCl2, 200 ÌM of each dNTP and 2.0 units of
Taq polymerase (Pharmacia). An initial denaturation of 10 min at
94°C was followed by 35 cycles of 1 min at 94 °C, 1 min at 49°C for
codon 12/13 or at 55°C for codon 61 and 1 min at 72°C, and a final
elongation step (8 min at 72°C). PCR products were screened for
mutations by the SSCP method on 6% polyacrylamide gels run at
5 W at 10°C and visualized by silver staining as described [29]. For
sequencing, PCR products were purified with the MicroSpin Col-
umns (Pharmacia). Both strands of DNA were sequenced by the
dideoxy method using Thermo-Sequenase according to the manufac-
turer’s protocol (Amersham Life Science, Slough, UK).
Statistical Methods. Associations of c-erbB2 amplification and K-
ras mutation with other clinicopathological factors were calculated
by ¯2 test. Probabilities of relapse-free survival and overall survival
(OS) were calculated using the method of Kaplan-Meier, statistical
differences were evaluated by log-rank test.
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Fig. 1. Analysis of c-erbB2 amplification by
fluorescent differential PCR. Electrophore-
togram of PCR products of c-erbB2 gene (98
bp) and the control locus y-IFN (85 bp) in
representative cases. The data were obtained
with an automated fluorescent DNA se-
quencer (ALF, Pharmacia) and analyzed
with Fragment ManagerTM software. The ab-
scissa of the electrophoretogram shows the
fragment size in base pairs. Lane 1 = Tumor
with low amplification; lane 3 = tumor with
high amplification; lane 27 = placenta with
no amplification (normal control).
Results
In DNA extracted from sections of a total of 112 pri-
mary endometrial cancers with reference tissue from the
same patients and in 90 benign, randomly chosen myo-
metrium samples, amplification of c-erbB2, c-myc and
int-2 was analyzed using fluorescent differential PCR
(fig. 1). c-erbB2 gene amplification (2- to 10-fold) was
observed in 21(18.6%) of the 112 endometrial carcinomas
examined. Amplification of c-myc and int-2 genes was
found in 3 (2.7%, 3- to 4-fold) and 5 (4.4%, 2- to 5-fold)
tumors, respectively (table 1). No amplification of the
three oncogenes could be detected in any of the benign
reference and additional myometrium samples analyzed.
All cases were screened for mutations at codon 12/13
and codon 61 of the K-ras oncogene by PCR-SSCP analy-
sis and direct double-stranded DNA sequencing. K-ras
mutations were observed in 13 (11.5%) of 112 carcino-
mas, 10 mutations were found in codon 12, and 3 in
codon 61 (table 1, fig. 2).
Due to the low number of c-myc and int-2 amplification,
no associations between amplification of these genes and
clinical factors were analyzed. Associations between c-
erbB2 gene amplification and K-ras mutation and patient
age and pathohistological factors were determined (ta-
ble 2). No significant associations between c-erbB2 gene
Table 1. Frequencies of c-erbB2, c-myc and
int-2 amplification and K-ras mutation in
112 endometrial cancers
n %
21 18.6
c-myc 3 2.7
int-2 5 4.4
K-ras
codon 10 12 8.9
codon 61 3 2.7
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Table 2. Amplification of c-erbB2 and mutation of K-ras correlated
with patients’ age and histopathological tumor characteristics of 112
endometrial cancers
Criteria Patients
(n = 112)
c-erbB2
amplification
K-ras
mutation
!50 8
650 104 p = 0.64 p = 0.65
Tumor
T1 70
T2 20 p = 0.56 p = 0.24
T3/4 22
Nodes
N0 97
N1/2 15 p = 0.22 p = 0.27
Metastases
M0 98
M1 14 p = 0.50 p = 0.15
Grade
I 51
II 30 p = 0.24 p = 0.39
III 21
Stage
I 69
II 18 p = 0.31 p = 0.18
III 14
IV 11
Family history
positive 16 p = 0.19 p = 0.21
negative 96
HRT
positive 17 p = 0.42 p = 0.37
negative 95
ER
negative 52
positive 50 p = 0.89 p = 0.23
ND 10
PgR
negative 51
positive 51 p = 0.62 p = 0.041
ND 10
ND = Not done; HRT = hormone replacement therapy.
Fig. 2. Demonstration of K-ras mutation by fluorescence-based
direct DNA sequencing. N = Normal control; T = tumor. The arrow-
heads indicate the mutations in the sequence. T1 shows a heterozy-
gous point mutation at codon 12 (GGT to GAT, Gly to ASP), T2
shows a homozygous point mutation at codon 61 (CAA to CAC, Gln
to His).
Table 3. Age, histopathological findings, staging, steroid hormone
receptor expression, amplification of c-erbB2 and K-ras mutation in
112 sporadic endometrial cancers correlated with DFS and OS
Criteria DFS OS
!50 vs. 650 years p = 0.16 p = 0.14
Tumor
T1 vs. T2 p ! 0.01 p ! 0.01
T1 vs. T3/4 p ! 0.01 p ! 0.01
T2 vs. T3/4 p = 0.014 p = 0.025
Nodes
N0 vs. N1 p = 0.14 p = 0.296
Metastases p = 0.048 p = 0.039
Grading
G1 vs. G2 p = 0.32 p = 0.721
G1 vs. G3 p ! 0.01 p ! 0.01
G2 vs. G3 p = 0.01 p = 0.015
Staging p = 0.13 p = 0.36
Family history
negative vs. positive p = 0.48 p = 0.52
HRT
negative vs. positive p = 0.78 p = 0.63
ER
negative vs. positive p = 0.64 p = 0.30
PgR
negative vs. positive p = 0.03 p = 0.016
Amplification of c-erbB2 p = 0.389 p = 0.222
Mutation of K-ras p = 0.339 p = 0.451
HRT = Hormone replacement therapy.
amplification and any clinical factor were observed. K-ras
gene mutation correlated significantly with higher PgR
expression (p ! 0.05), but with none of the other clinical
parameters and survival of the patients (table 2). For dis-
ease-free survival (DFS) and overall survival (OS) clinical
parameters including PgR expression revealed significant
prognostic value. For c-erbB2 amplification and K-ras mu-
tation no prognostic information was achieved (table 3).
Discussion
The systemic management of endometrial cancer pa-
tients is mainly based on histopathological criteria such as
myometrial invasion, tumor grading, and extrauterine
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tumor spread. However, these parameters are evidently
unable to sufficiently characterize the biological behavior
of endometrium cancer [1, 2]. Analyses of genetic altera-
tions are relevant for the understanding of tumor genetics
and may provide prognostic information for the individu-
al patient [15, 30]. The role of oncogene activation in
endometrial cancer is incompletely characterized. Most of
the studies published on oncogene amplification in endo-
metrial cancer only examined small numbers of cases,
often with conflicting results [10–12, 31–33]. In this
study, amplification of c-erbB2, c-myc, and int-2 were
determined in 112 endometrial cancers. To date, this is
the largest study performed on endometrial cancer bear-
ing oncogene amplification with differential PCR. Am-
plification of c-erbB2, c-myc and int-2 were found in 18.6,
2.7 and 4.4% of endometrial cancers analyzed. The de-
tected rates of oncogene amplification are in agreement
with previous studies [10–12, 31–33].
Amplification of c-myc or int-2 is very low, implicating
a subordinate role of these oncogenes in the development
of sporadic endometrial cancer. Numerous studies have
demonstrated that amplification and overexpression of c-
erbB2 in endometrial cancer correlated with clinical and
pathohistological factors such as histological grade. Fur-
thermore, it was suggested that c-erbB2 is of prognostic
value [10–12, 31, 32]. In contrast to these findings, we
could not demonstrate any significant correlation be-
tween the amplification of the c-erbB2 gene and clinical
factors, as well as the DFS and OS of the patients. These
results have been supported by Monk et al. [33]. Sample
size, tumor histology or technical variations may account
for this discrepancy. Further studies in strictly defined
populations with standard analytical techniques may
have to clarify the prognostic significance of c-erbB2
amplification in endometrial cancer.
A rare genetic phenomenon is the mutation of an onco-
gene. Mutations in the K-ras oncogene occur in 10–50%
of several tumor types including endometrial cancer [16–
18]. K-ras mutations also have been found in endometrial
hyperplasia, suggesting that activation of K-ras represents
an early event in the development of endometrial cancer
[16]. In this study, K-ras mutations could be detected in
11.5% of endometrial cancers. There were no correlations
between K-ras point mutation and clinical stage, histologi-
cal grade and clinical outcome of the patients, in agree-
ment with other studies [16–18, 34]. Mutations of the ras
oncogene alter the ras product by abolishing their intrin-
sic GTPase activity, which results in autonomous cell
growth [35]. Activation of the guanine nucleotide binding
protein ras enhance estrogen-induced and antiestrogen
(tamoxifen)-induced transcriptional activity of the ER
activation function 1 [36, 37]. These findings are in agree-
ment with the results of this study. A significant correla-
tion was found between ER-dependent PgR expression
and activating K-ras mutations. This suggests that en-
hanced activity of the ER activation function 1 by stimu-
lating phosphorylation mediated through mutational acti-
vation of the ras-MAPK cascade may be one mechanism
of hormone independence of endometrial cancer. This
may contribute to the development of (anti-)hormone
resistance of steroid-receptor-positive endometrial can-
cer.
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